Company intelligence / Profile preview

Synthekine

Ownership: Private
Development stage: Preclinical

Overview

Currently conducting Phase 1 study of STK-009 + SYNCAR-001 for CD19+ hematologic malignancies (NCT05665062). STK-009 dose escalation is ongoing with a fixed dose of SYNCAR-001 cells that is significantly lower than traditional CD19 CAR-T therapies. Preclinical studies showed significantly more complete responses compared to conventional CD19 CAR-T cell therapy in xenograft efficacy models.

Therapeutic areas: OncologyImmunology
Modalities: Engineered cytokine therapeuticsCAR-T cell therapies
Industry: Biotech

Drug pipeline

14 assets

stk-012

13 more assets in the full pipeline.

Request access →

Partnerships

Mentioned having partnerships but specific companies not named

Beyond the preview

Go deeper on Synthekine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthekine.

Explore the full profile